Bayer and Johnson & Johnson’s new oral Factor Xa anticoagulant, rivaroxaban, has shown superiority over Sanofi-Aventis’ Lovenox (enoxaparin), but the agent is still under close watch for potential liver toxicity concerns, according to physicians interviewed by Pharmawire.
AstraZeneca’s Exanta, an orally active direct thrombin inhibitor, was pulled off the market in 2006 due to concerns over liver toxicity and a report of serious liver damage. There have been safety concerns over potential liver toxicity concerns with oral anticoagulants in general, following on from AstraZeneca’s failure in 2006, physicians said.
Dr Alexander Turpie, Principal Investigator in the RECORD program and Professor of Medicine at McMaster University in Canada said in the short-term, there is no evidence of ongoing liver toxicity.
More
3 comments:
Exanta was not "pulled of the market in 2006" for the very obvious reason that it never made it to launch. It's marketing authorisation was rejected by FDA over concerns about hepatotoxicity.
It did get a licence and was marketed in some countries.
http://www.astrazeneca.com/pressrelease/5217.aspx
Here's AZ's withdrawal press release.
Post a Comment